Back to top

vaccines: Archive

Sundeep Ganoria

Buy Moderna Stock Before Q3 Earnings? Here's What to Know

MRNA's Q3 earnings are expected to arrive amid a 652% stock rally, premium valuation and promising cancer therapy data. Should investors buy, sell or hold?

MRNANegative Net Change GSKNegative Net Change PFENegative Net Change MRKNegative Net Change

Sundeep Ganoria

GSK vs. Moderna: Which Large-Cap Biotech Stock Offers More Growth?

GSK's Specialty Medicines growth, deep pipeline and dividend offer a compelling case against MRNA's oncology potential and premium valuation.

GSKNegative Net Change MRNANegative Net Change PFENegative Net Change MRKNegative Net Change

Sundeep Ganoria

Moderna's Respiratory Portfolio Expands: Can It Reduce COVID Reliance?

MRNA expands beyond COVID-19 with new RSV, flu and combination vaccines, but fierce competition could challenge its efforts to diversify revenue.

MRNANegative Net Change GSKNegative Net Change PFENegative Net Change BNTXNegative Net Change

Sundeep Ganoria

MRNA Stock Gains Over $4B in a Week: Time to Buy, Hold or Sell?

Moderna gains $4.2 billion in a week on cancer-vaccine optimism and Nasdaq-100 inclusion. Can its growth prospects justify its premium valuation?

MRNANegative Net Change PFENegative Net Change MRKNegative Net Change BNTXNegative Net Change

Sundeep Ganoria

Vaccine Stocks Rally on Reports of U.S.-led Push for Cancer Vaccines

MRNA, BNTX and NVAX shares rally after reports of a planned NIH-backed initiative to accelerate personalized cancer vaccines and expand research funding.

MRNANegative Net Change NVAXNo Net Change BNTXNegative Net Change RHHBYNegative Net Change MRKNegative Net Change

Sundeep Ganoria

Moderna's Nasdaq-100 Entry: What Does It Mean for the Stock?

MRNA's Nasdaq-100 entry follows a 566% stock surge and stronger cancer therapy prospects, potentially boosting demand from index-tracking funds.

MRNANegative Net Change MRKNegative Net Change SKYDNegative Net Change